2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005, 171(4): 388-416.
[3]
3. Miller BW, Brennan DC, Korenblat PE, et al. Common variable immunodeficiency in a renal transplant patient with severe recurrent bacterial infection: a case report and review of the literature. Am J Kidney Dis, 1995, 25(6): 947-951.
[4]
4. Passalacqua JA, Wiland AM, Fink JC, et al. Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients. Transplantation, 1999, 68(4): 535-940.
[5]
5. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med, 1998, 338(24): 1741-1751.
7. Ducloux D, Courivaud C, Bamoulid J, et al. Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol, 2010, 21(5): 868-875.
[8]
8. Schurmann M, Schurmann D, Schindler R, et al. Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transpl Immunol, 2013, 28(4): 159-163.
[9]
9. Tu GW, Ju MJ, Han Y, et al. Moderate-dose glucocorticoids as salvage therapy for severe pneumonia in renal transplant recipients: a single-center feasibility study. Ren Fail, 2014, 36(2): 202-209.
[10]
10. Dupont PJ, Manuel O, Pascual M. Infection and chronic allograft dysfunction. Kidney Int Suppl, 2010, (119): S47-53.
[11]
11. Dizdar OS, Ersoy A, Akalin H. Pneumonia after kidney transplant: incidence, risk factors, and mortality. Exp Clin Transplant, 2014, 12(3): 205-211.
[12]
12. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med, 2008, 121(3): 219-225.
[13]
13. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med, 2006, 32(3): 469-472.
[14]
14. Menendez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax, 2009, 64(11): 987-992.
[15]
15. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax, 2008, 63(5): 447-452.
[16]
16. Bozza FA, Shah AM, Weyrich AS, et al. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol, 2009, 40(2): 123-134.
[17]
17. Thiery-Antier N, Binquet C, Vinault S, et al. Is thrombocytopenia an early prognostic marker in septic shock?. Crit Care Med, 2016, 44(4): 764-772.
[18]
18. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med, 2004, 350(7): 647-654.
[19]
19. Hopkins WE, Chen Z, Fukagawa NK, et al. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation, 2004, 109(23): 2872-2877.
[20]
20. Shor R, Rozenman Y, Bolshinsky A, et al. BNP in septic patients without systolic myocardial dysfunction. Eur J Intern Med, 2006, 17(8): 536-540.
[21]
21. Li J, Ye H, Zhao L. B-type natriuretic peptide in predicting the severity of community-acquired pneumonia. World J Emerg Med, 2015, 6(2): 131-136.
